A recent paper in the Frontiers in Medicine states that
An underutilized intervention for long COVID is low dose naltrexone, which has an established safety profile for a variety of conditions. ‘Naltrexone is a non-selective opioid antagonist currently approved by the US Food and Drug Administration (FDA) for the treatment of alcohol and opioid dependence and is prescribed at 50–150 mg daily. At doses below 5 mg, it is considered low-dose naltrexone (LDN), exhibits anti-inflammatory and analgesic properties, and has been used off-label to reduce severity of symptoms in conditions such as fibromyalgia, multiple sclerosis, complex regional pain syndrome, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and Crohn’s disease. LDN is widely available with a prescription, also at a low cost, and is associated with minimal side effects. LDN has been associated with improvement of several clinical symptoms related to long COVID such as fatigue, poor sleep quality and pattern, brain fog, post-exertional malaise, headache, and demonstrated reduction of symptoms and improvement of functionality. In patients living with long COVID presenting with neuropsychiatric symptoms, fatigue, or exertional intolerance, consider utilization or adjunct therapy with LDN.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1430444/full
